Company Filing History:
2 out of 91 
1 out of 12 Years Active: 2010-2022
Title: **Elfriede Noessner: A Pioneer in Fusion Protein Innovations**
Introduction
Elfriede Noessner, an accomplished inventor based in Munich, Germany, has made significant contributions to the field of immunology through her innovative work on fusion proteins. With a total of three patents to her name, her discoveries are instrumental in developing therapeutic strategies for targeting diseases such as cancer.
Latest Patents
Noessner's latest patents revolve around the design of fusion proteins that combine vital immunological elements. One notable invention details fusion proteins comprising an extracellular domain featuring a polypeptide derived from PD-1 or CD40L at its N-terminus, a transmembrane domain, and an intracellular domain containing a polypeptide derived from 4-1BB or CD28 at its C-terminus. Additionally, it includes nucleic acid molecules encoding these fusion proteins, vectors that incorporate them, and host cells containing these vectors. The application of these inventions is particularly promising in developing pharmaceutical compositions aimed at treating diseases associated with PD-1/PD-L2 or CD40 binding and related expressions, including specific cancers and chronic viral infections.
Another remarkable patent from Noessner addresses the treatment of tumors exhibiting low or aberrant MHC expression. This invention provides therapeutic compositions that include non-MHC-restricted T-cells/NK-cells combined with MHC-restricted T-cells, especially utilizing LAK cells. This combination is vital in effectively targeting tumors that might otherwise evade immune detection, contributing to a balanced immune response against tumor variants.
Career Highlights
Elfriede Noessner has worked in esteemed organizations, notably at the Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH). Her career holds a rich history of innovation in protein engineering, particularly focusing on therapeutic applications that target complex diseases.
Collaborations
Throughout her career, Noessner has collaborated with talented individuals in her field, including notable coworkers Elisabeth Weiss and Dolores Schendel. These collaborations have undoubtedly enhanced the research initiatives she has been involved in and further propelled advancements in immunotherapy.
Conclusion
Elfriede Noessner exemplifies the spirit of innovation within the scientific community. Her pioneering inventions in fusion protein technology not only advance academic research but also hold potential for revolutionary treatments in combatting serious health conditions. Through her dedication and collaboration with fellow researchers, Noessner continues to shape the future of immunological therapies.